Section 870.3605 - Pacing system analyzer(a)Identification. A pacing system analyzer (PSA) is a prescription device that combines the functionality of a pacemaker electrode function tester (§ 870.3720 ) and an external pacemaker pulse generator (EPPG) (§ 870.3600 ). It is connected to a pacemaker lead and uses a power supply and electronic circuits to supply an accurately calibrated, variable pacing pulse for measuring the patient's pacing threshold and intracardiac R-wave potential. A PSA may be a single, dual, or triple chamber system and can simultaneously deliver pacing therapy while testing one or more implanted pacing leads.(b)Classification. Class II (special controls). The special controls for this device are: (1) Appropriate analysis/testing must validate electromagnetic compatibility (EMC) within a hospital environment.(2) Electrical bench testing must demonstrate device safety during intended use. This must include testing with the specific power source (i.e., battery power, AC mains connections, or both).(3) Non-clinical performance testing data must demonstrate the performance characteristics of the device. Testing must include the following: (i) Testing must demonstrate the accuracy of monitoring functions, alarms, measurement features, therapeutic features, and all adjustable or programmable parameters as identified in labeling;(ii) Mechanical bench testing of material strength must demonstrate that the device and connection cables will withstand forces or conditions encountered during use;(iii) Simulated use analysis/testing must demonstrate adequate user interface for adjustable parameters, performance of alarms, display screens, interface with external devices (e.g. data storage, printing), and indicator(s) functionality under intended use conditions; and(iv) Methods and instructions for cleaning the pulse generator and connection cables must be validated.(4) Appropriate software verification, validation, and hazard analysis must be performed.(5) Labeling must include the following:(i) The labeling must clearly state that these devices are intended for use in a hospital environment and under the supervision of a clinician trained in their use;(ii) Connector terminals should be clearly, unambiguously marked on the outside of the PSA. The markings should identify positive (+) and negative (-) polarities. Dual chamber devices should clearly identify atrial and ventricular terminals. Triple chamber devices should clearly identify atrial, right ventricular, and left ventricular terminals;(iii) The labeling must list all pacing modes available in the device;(iv) Labeling must include a detailed description of any special capabilities (e.g., overdrive pacing or automatic mode switching);(v) Labeling must limit the use of external pacing to the implant procedure; and(vi) Appropriate electromagnetic compatibility information must be included. 81 FR 22350 , Apr. 18, 2016